Selected markers in early prediction of preeclampsia

Czech version

Authors: M. Haško; K. Biringer; K. Biskupská Boďová; J. Danko
Authors‘ workplace: Gynekologicko-pôrodnícka klinika JLF UK a UNM, Martin, prednosta prof. MUDr. J. Danko, CSc.
Published in: Ceska Gynekol 2011; 76(2): 135-139

Overview

Objective:
Review of actual trends in early prediction of preeclampsia.

Subject:
Literature review.

Setting:
Department of Gynecology and Obstetrics, Jessenius Faculty of Medicine, Comenius University, Martin, Slovak Republic.

Subject and method:
Literature review of markers used in early prediction of preeclampsia. Review of their reliability and possible advantage of combination.

Conclusion:
Preeclampsia is a major cause of maternal and perinatal morbidity and mortality worldwide. Onset of clinic symptomes of preeclampsia can appear after 20 weeks of gestation. To find a single marker, or their combination, in early prediction of preeclampsia is one of the goals of modern perinatology. We look at some of the potential markers, which can fulfil these criteria.

Key words:
preeclampsia, biochemical screening, doppler ultrasonography, PP 13, angiogenesis.

Sources

1. American College of Obstetricians and Gynecologists. ACOG practice bulletin. Diagnosis and management of preeclampsia and eclampsia. Int J Gynaecol Obstet, 2002, 77, 33, p. 67-75.

2. Biringer, K., Haško, M., Cuľbová, M., et al. Patologická gravidita a Dopplerovská sonografia v druhej polovici tehotnosti. Gynekol Prax, 2008,6,3, s. 163-170.

3. Burger, O., Pick, E., Zwickel, J. Placental protein 13 (PP-13): Effect on cultured trophoblasts and its detection in human body fluids in normal and pathological pregnancies. Placenta, 2004, 25, p. 608-622.

4. Carty, DM., Delles, C., Dominiczak, AF. Novel biomarkers for predicting preeclampsia. Trends Cardiovasc Med, 2008, 18, 5, p.186-194.

5. Chaiworapongsa, T., Romero, R., Kim, YM., et al. Plasma soluble vascular endothelial growth factor receptor-1 concentration is elevated prior to the clinical diagnosis of pre-eclampsia. J Matern Fetal Neonatal Med, 2005, 17, p. 3-18.

6. Clark, DE., Smith, SK., He, Y., et al. A vascular endothelial growth factor antagonist is produced by the human placenta and released into the maternal circulation. Biol Reprod, 1998, 59, p. 1540-1548.

7. Cnossen, JS., Morris, RK., Riet, G., et al. Use of uterine artery Doppler ultrasonography to predict pre-eclampsia and intrauterine growth restriction: a systematic review and bivariable meta-analysis. CMAJ, 2008, 178, 6, p. 701-711.

8. Cooper, JC., Sharkey, AM., Charnock-Jones, DS. VEGF mRNA levels in placentae from pregnancies complicated by pre-eclampsia. Br J Obstet Gynaecol, 1996, 103, p. 1191-1196.

9. Costa, S., Proctor, L., Dodd, J., et al. Screening for placental insufficiency in high-risk pregnancies: is earlier better? Placenta, 29, 12, p. 1034-1040.

10. De Vivo, A., Baviera, G., Giordano, D., et al. Endoglin, PlGF and sFlt-1 as markers for predicting pre-eclampsia. Acta Obstet Gynecol Scand, 2008, 87, 8, p. 837-842.

11. Gonen, R., Shahar, R., Grimpel, YI., et al. Placental pr ein 13 as an early marker for pre-eclampsia: a prospective longitudinal study. BJOG, 2008, 115, 12, p. 1465-1472.

12. Grill, S., Rusterholz, C., Zanetti-Dällenbach, R. Potential markers of preeclampsia – a review. Reprod Biol Endocrinol, 2009, 14, 7, p. 70.

13. Gudmundsson, S., Korszun, P., Olofsson, P., et al. New score indicating placental vascular resistance. Acta Obstet Gynecol Scand, 2003, 82, 9, p. 807-812.

14. Lee, ES., Oh, MJ., Jung, JW. The levels of circulating vascular endothelial growth factor and soluble FLT-1 in pregnancies complicated by preeclampsia. J Korean Med Sci, 2007, 22, p. 94‑98.

15. Levine, RJ., Maynard, SE., Qian, C., et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med, 2004, 350, p. 672-683.

16. Levine, RJ., Thadhani, R., Qian, C., et al. Urinary placental growth factor and risk of preeclampsia. JAMA, 2005, 293, p. 77‑85.

17. Nicolaides, KH., Bindra, R., Turan, OM. A novel approach to first-trimester screening for early pre-eclampsia combining serum PP-13 and Doppler ultrasound. Ultrasound Obstet Gynecol, 2006, 27, p. 13-17.

18. Phupong, V., Dejthevaporn, T., Tanawattanacharoen, S., et al. Predicting the risk of preeclampsia and small for gestational age in nts by uterine artery Doppler in low-risk women. Arch Gynecol Obstet, 2003, 268, p. 158-161.

19. Rana, S., Karumanchi, SA., Levine, RJ. Sequential changes in antiangiogenic factors in early pregnancy and risk of developing preeclampsia. Hypertension, 2007, 50, p. 137-142.

20. Robinson, CJ., Johnson, DD., Chang, EY. et al. Evaluation of placenta growth factor and soluble Fms-like tyrosine kinase 1 receptor levels in mild and severe preeclampsia. Am J Obstet Gynecol, 2006, 195, p. 255-259.

21. Romero, R., Kusanovic, JP., Than, NG., et al. First-trimester maternal serum PP13 in the risk assessment for preeclampsia. Am J Obstet Gynecol, 2008, 199, 122, p.e1-122.e11.

22. Romero, R., Nien, JK., Espinoza, J., et al. A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate. J Matern Fetal Neonatal Med, 2008, 21, p. 9-23.

23. Salahuddin, S., Lee, Y., Vadnais, M., et al. Diagnostic utility of soluble fms-like tyrosine kinase 1 and soluble endoglin in hypertensive diseases of pregnancy. Am J Obstet Gynecol, 2007, 197, p. 28.e1-6.

24. Sekizawa, A., Purwosunu, Y., Yoshimura, S., et al. PP13 mRNA expression in trophoblasts from preeclamptic placentas. Reprod Sci, 2009, 16, p. 408-413.

25. Stepan, H., Kramer, T., Faber, R. Maternal plasma concentrations of soluble endoglin in pregnancies with intrauterine growth restriction. J Clin Endocrinol Metab, 2007, 92, p. 2831-2834.

26. Stepan, H., Unversucht, A., Wessel, N., et al. Predictive value of maternal angiogenic factors in second trimester pregnancies with abnormal uterine perfusion. Hypertension, 2007, 49, 4, p. 818-824.

27. St-Jacques, S., Forte, M., Lye, SJ., et al. Localization of endoglin, a transforming growth factor-beta binding protein, and of CD44 and integrins in placenta during the first trimester of pregnancy. Biol Reprod, 1994, 51, p. 195, p. 255-259.

21. Romero, R., Kusanovic, JP., Than, NG., et al. First-trimester maternal serum PP13 in the risk assessment for 195, p. 255-259.

21. Romero, R., Kusanovic, JP., Than, NG., et al. First-trimester maternal serum PP13 in the risk assessment for tardácie a preeklampsie pomocou ultrazvukových markerov. Prakt Gynek, 2007, 14, 2, p. 46-54.

29. Venkatesha, S., Toporsian, M., Lam, C., et al. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med, 2006, 12, p. 642-649.

30. Verlohren, S., Galindo, A., Schlembach, D., et al. An automated method for the determination of the sFlt-1/PIGF ratio in the assessment of preeclampsia. Am J Obstet Gynecol, 2010, 202, 2, p. 161.e1-161.e11.

31. Višňovský, J. Vyšetrenie cirkulácie v pôrodníctve. Martin: Osveta, 2002, 200 s.

32. Wikstrom, AK., Larsson, A., Eriksson, UJ., et al. Placental growth factor and soluble FMS-like tyrosine kinase-1 in early-onset and late-onset preeclampsia. Obstet Gynecol, 2007, 109, p. 1368-1374.